Thymopentin added to inhaled triple therapy in stable COPD
Randomized study in people · 2024
- What was studied
- 150 patients with stable chronic obstructive pulmonary disease, 75 per group.
- Main finding
- Study-defined overall response · 94.67% with thymopentin plus inhaled therapy versus 82.67% with inhaled therapy alone (p<0.05).
Reported findings and study design
Reported findings
The authors report random assignment. Both groups used inhaled budesonide, glycopyrronium and formoterol (two inhalations twice a day). The intervention group also received thymopentin 10 mg subcutaneously twice weekly for three months.
Population or model 150 patients with stable chronic obstructive pulmonary disease, 75 per group.
Dose, route and schedule
The authors report random assignment. Both groups used inhaled budesonide, glycopyrronium and formoterol (two inhalations twice a day). The intervention group also received thymopentin 10 mg subcutaneously twice weekly for three months.
Protocol source ↗ · Publisher’s original Chinese abstract and bilingual metadata.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Study-defined overall response | 94.67% with thymopentin plus inhaled therapy versus 82.67% with inhaled therapy alone (p<0.05). | |
| Lung function and subsequent events | The abstract reports better spirometry and fewer exacerbations and readmissions with adjunctive thymopentin. It omits the group-level values for these outcomes. |
The abstract gives no details on allocation concealment or masking. The overall response measure is specific to this study. The Chinese methods identify the comparator as inhaled triple therapy.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- The abstract gives no details on allocation concealment or masking. The overall response measure is specific to this study. The Chinese methods identify the comparator as inhaled triple therapy.
Source details
Publisher’s original Chinese abstract and bilingual metadata.
Sources checked
Added to the library
Citation
Wei Chen, Bayinsang, Xuelin Jiang, Xulin Huang, Shuai Shi. Thymopentin added to inhaled triple therapy in stable COPD Drugs & Clinic 39(12), 3125–3129
Study source ↗ · DOI 10.7501/j.issn.1674-5515.2024.12.018 · Bibliography entry · Link to this summary